» Articles » PMID: 7550854

Serum Pepsinogen in Screening for Gastric Cancer

Overview
Journal J Gastroenterol
Specialty Gastroenterology
Date 1995 Aug 1
PMID 7550854
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

To establish a sensitive and efficient screening method for gastric cancer using serum pepsinogen, we investigated the characteristics of serum pepsinogen I and II levels and the I/II ratio and their cut-off points. We found that the pepsinogen I level and the I/II ratio were significantly lower in patients with gastric cancer than in control subjects, especially in patients with cancers of the differentiated type, the elevated type, and the depressed type without ulceration. However, sex, depth of invasion, and location of tumor did not correlate with the pepsinogen levels. A suitable cut-off point in screening for gastric cancer was a pepsinogen I level of less than 50 ng/ml and a I/II ratio of less than 3.0, as determined by receiver operator characteristics curves. The sensitivity, the specificity, and the accuracy of detection for all types of gastric cancer were approximately 55%, 75%, and 72%, respectively. If restricted to cancers of the elevated and the depressed type without ulceration, the sensitivity was approximately 85%, and the specificity and accuracy were approximately 76% and 77%, respectively. These results suggest that, in screening for gastric cancer when using pepsinogen levels and morphological examinations, the suitable cut-off point in regard to specificity is as stated above. However, regarding sensitivity, when the pepsinogen method is used alone, a pepsinogen I level of less than 70 ng/ml and a I/II ratio of less than 3.0 is acceptable.

Citing Articles

Smoking history and severe atrophic gastritis assessed by pepsinogen are risk factors for the prevalence of synchronous gastric cancers in patients with gastric endoscopic submucosal dissection: a multicenter prospective cohort study.

Hatta W, Koike T, Asonuma S, Okata H, Uno K, Oikawa T J Gastroenterol. 2023; 58(5):433-443.

PMID: 36786863 DOI: 10.1007/s00535-023-01967-y.


Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case-Control Study Using the PLCO Cancer Screening Trial Data.

In H, Sarkar S, Ward J, Friedmann P, Parides M, Yang J Cancer Epidemiol Biomarkers Prev. 2022; 31(7):1426-1432.

PMID: 35534235 PMC: 9268394. DOI: 10.1158/1055-9965.EPI-21-1328.


Screening for gastric cancer in China: Advances, challenges and visions.

Fan X, Qin X, Zhang Y, Li Z, Zhou T, Zhang J Chin J Cancer Res. 2021; 33(2):168-180.

PMID: 34158737 PMC: 8181866. DOI: 10.21147/j.issn.1000-9604.2021.02.05.


Standard magnifying narrow-band imaging endoscopy for diagnosis of infection and gastric precancerous conditions.

Cho J, Jeon S, Jin S, Park S World J Gastroenterol. 2021; 27(18):2238-2250.

PMID: 34025076 PMC: 8117737. DOI: 10.3748/wjg.v27.i18.2238.


Role of Serum Pepsinogen II and Status in the Detection of Diffuse-Type Early Gastric Cancer in Young Individuals in South Korea.

Baek S, Kim N, Kwon Y, Lee H, Kim H, Lee J Gut Liver. 2019; 14(4):439-449.

PMID: 31533397 PMC: 7366145. DOI: 10.5009/gnl19091.


References
1.
Saito T . [Studies on pepsinogen production in advanced gastric cancer tissue]. Nihon Geka Gakkai Zasshi. 1989; 90(8):1205-12. View

2.
Kodoi A, Haruma K, Yoshihara M, Shimamoto T, Watanabe C, Okamoto S . [A clinical study of pepsinogen I and II producing gastric carcinomas]. Nihon Shokakibyo Gakkai Zasshi. 1993; 90(12):2971-8. View

3.
Maruyama T, Noda Y, Kumamoto Y, Nishizawa K, Furuya Y, Iwai K . [Estimation of frequency, population doses and stochastic risks in stomach mass screening examinations in Japan, 1980]. Nihon Igaku Hoshasen Gakkai Zasshi. 1987; 47(7):971-82. View

4.
Jaskiewicz K, Louwrens H . Chronic atrophic gastritis in a population at risk for gastric carcinoma. Anticancer Res. 1991; 11(2):835-9. View

5.
SAMLOFF I . Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastroenterology. 1971; 61(2):185-8. View